What Has Been the Growth of the Atherosclerosis Drugs Market So Far?
The atherosclerosis drugs market has seen considerable growth due to a variety of factors.
•There has been a consistent expansion of the market size for atherosclerosis drugs in the past few years. It is projected to increase from $49.89 billion in 2024 to $51.42 billion in 2025, boasting a compound annual growth rate (CAGR) of 3.1%.
Factors contributing to the growth during the historical period include cholesterol control, blood pressure management, the implementation of smoking cessation programs, research and development initiatives, and advancements in diagnostics.
What Are the Future Growth Projections for the Atherosclerosis Drugs Market?
The atherosclerosis drugs market is expected to maintain its strong growth trajectory in upcoming years.
• Predictions indicate a consistent surge in the size of the atherosclerosis drugs market in the forthcoming years. By 2029, the market is projected to expand to $59.38 billion, marking a compound annual growth rate (CAGR) of 3.7%.
The anticipated growth within this period can be credited to the advent of new therapy methods, precision medicine, immunotherapy and inflammation, as well as advances in lipid management and regulatory support. Biologic therapies, gene therapy and editing, combination therapies, personalized treatment techniques, telemedicine, and remote monitoring are the primary trends expected within the forecast era.
What Are The Core Factors Supporting Growth In The Atherosclerosis Drugs Market?
The anticipated increase in cardiovascular diseases is likely to accelerate the growth of the atherosclerosis drug market. Cardiovascular diseases encompass all conditions affecting the heart and blood vessels, with atherosclerosis specifically describing the accumulation of fats, cholesterol, and other substances on a person's artery walls. Atherosclerosis is marked by plaque buildup inside the arteries that provoke cardiovascular diseases such as stroke and coronary heart disease. Atherosclerosis medications are utilized to combat cardiovascular diseases by mitigating complications risks and managing underlying conditions such as high cholesterol levels and blood clot formation. For example, the Minnesota Department of Health released data in September 2024 indicating that roughly 30% of Minnesota adults, nearly 1.4 million people, reported suffering from high blood pressure in 2023. Moreover, hypertensive diseases were noted as the primary or contributing cause of death for 14,225 residents in 2022, accounting for close to 28% of all fatalities in the state. Hence, the widespread prevalence of cardiovascular diseases is expected to boost the atherosclerosis drug market.
What Are The Major Segments Within The Global Atherosclerosis Drugs Market?
The atherosclerosis drugs market covered in this report is segmented –
1) By Drug Class: Anti-Platelet Medications, Fibric Acid And Omega-3 Fatty Acid Derivatives, Angiotensin-Covering Enzyme (ACE) Inhibitors, Diuretics, Cholesterol Lowering Medication, Beta Blockers, Calcium Channel Blockers, Other Drug Classes
2) By Route Of Administration: Oral, Injectable
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Other Distribution Channels
Subsegments:
1) By Anti-Platelet Medications: Aspirin, Clopidogrel, Ticagrelor
2) By Fibric Acid And Omega-3 Fatty Acid Derivatives: Fenofibrate, Gemfibrozil, Omega-3 Fatty Acid Supplements
3) By Angiotensin-Covering Enzyme (ACE) Inhibitors: Lisinopril, Enalapril, Ramipril
4) By Diuretics: Thiazide Diuretics, Loop Diuretics, Potassium-Sparing Diuretics
5) By Cholesterol Lowering Medication: Statins, PCSK9 Inhibitors, Bile Acid Sequestrants
6) By Beta Blockers: Metoprolol, Atenolol, Carvedilol
7) By Calcium Channel Blockers: Amlodipine, Diltiazem, Verapamil
8) By Other Drug Classes: Anticoagulants, Vasodilators, Cholesterol Absorption Inhibitors
Pre-Book The Atherosclerosis Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Trends Are Expected To Transform The Atherosclerosis Drugs Market?
In the atherosclerosis drugs market, product innovation is emerging as a critical trend. This involves major players in the market developing inventive drugs and gaining approval to maintain their market position. For example, in March 2024, Novo Nordisk A/S, a healthcare company based in Denmark, declared they had received approval for Wegovy (semaglutide), a drug aimed at reducing cardiovascular risk in individuals who are overweight or obese. This drug is the first of its kind designed to mitigate major cardiovascular event risk in adults with established cardiovascular disease and overweight or obesity. This offers a fresh therapeutic alternative for this population group at high risk. The drug's dual functionality not only helps manage obesity but could also play a significant role in averting severe cardiovascular issues, likely enhancing patient results and extending lifespan.
Who Are the Key Players in the Atherosclerosis Drugs Market?
Major companies operating in the atherosclerosis drugs market include:
• Johnson And Johnson Private Limited
• Pfizer Inc.
• F. Hoffmann-La Roche AG
• AbbVie Inc.
• Bayer AG
• Janssen Pharmaceuticals Inc.
• Novartis AG
• Merck And Co.Inc.
• Sanofi S.A.
• AstraZeneca plc
• Abbott Laboratories
• GSK plc.
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Gilead Sciences Inc.
• Amgen Inc.
• Novo Nordisk A/S
• Boehringer Ingelheim International GmbH
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Otsuka Holdings Co. Ltd.
• Regeneron Pharmaceuticals Inc.
• Biogen Inc.
• Lupin Limited
• Alnylam Pharmaceuticals Inc.
• Ionis Pharmaceuticals Inc.
• Amarin Corporation plc
• Esperion Therapeutics Inc.
• Kowa Pharmaceuticals America Inc.
• Anthera Pharmaceuticals Inc.
What Is The Most Dominant Region In The Atherosclerosis Drugs Market?
North America was the largest region in the atherosclerosis drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atherosclerosis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
